par de Azambuja, Evandro
;Abdel Azim, Hatem Hamdy
;Holmes, Andrew A.P.;Holmes, Eileen;Piccart-Gebhart, Martine
;Di Cosimo, Serena;Swaby, Ramona R.F.;Untch, Michael;Jackisch, Christian;Lang, Istvan;Smith, Ian;Boyle, Frances;Xu, Binghe;Barrios, Carlos;Perez, Edith A;Kim, Sung-Bae;Kuemmel, Sherko;Huang, Chiun Sheng;Vuylsteke, Peter;Hsieh, Ruey Kuen;Gorbunova, Vera;Eniu, Alexandru;Dreosti, Lydia;Tavartkiladze, Natalia;Gelber, Richard;Eidtmann, Holger;Baselga, José
Référence Lancet oncology, 15, 10, page (1137-1146)
Publication Publié, 2014
;Abdel Azim, Hatem Hamdy
;Holmes, Andrew A.P.;Holmes, Eileen;Piccart-Gebhart, Martine
;Di Cosimo, Serena;Swaby, Ramona R.F.;Untch, Michael;Jackisch, Christian;Lang, Istvan;Smith, Ian;Boyle, Frances;Xu, Binghe;Barrios, Carlos;Perez, Edith A;Kim, Sung-Bae;Kuemmel, Sherko;Huang, Chiun Sheng;Vuylsteke, Peter;Hsieh, Ruey Kuen;Gorbunova, Vera;Eniu, Alexandru;Dreosti, Lydia;Tavartkiladze, Natalia;Gelber, Richard;Eidtmann, Holger;Baselga, JoséRéférence Lancet oncology, 15, 10, page (1137-1146)
Publication Publié, 2014
Article révisé par les pairs
| Titre: |
|
| Auteur: | de Azambuja, Evandro; Abdel Azim, Hatem Hamdy; Holmes, Andrew A.P.; Holmes, Eileen; Piccart-Gebhart, Martine; Di Cosimo, Serena; Swaby, Ramona R.F.; Untch, Michael; Jackisch, Christian; Lang, Istvan; Smith, Ian; Boyle, Frances; Xu, Binghe; Barrios, Carlos; Perez, Edith A; Kim, Sung-Bae; Kuemmel, Sherko; Huang, Chiun Sheng; Vuylsteke, Peter; Hsieh, Ruey Kuen; Gorbunova, Vera; Eniu, Alexandru; Dreosti, Lydia; Tavartkiladze, Natalia; Gelber, Richard; Eidtmann, Holger; Baselga, José |
| Informations sur la publication: | Lancet oncology, 15, 10, page (1137-1146) |
| Statut de publication: | Publié, 2014 |
| Sujet CREF: | Cancérologie |
| MeSH keywords: | Administration, Oral |
| Adult | |
| Aged | |
| Antibodies, Monoclonal, Humanized -- adverse effects -- therapeutic use | |
| Antineoplastic Combined Chemotherapy Protocols -- therapeutic use | |
| Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology | |
| Chemotherapy, Adjuvant | |
| Confidence Intervals | |
| Disease-Free Survival | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Infusions, Intravenous | |
| Maximum Tolerated Dose | |
| Middle Aged | |
| Neoadjuvant Therapy | |
| Neoplasm Invasiveness -- pathology | |
| Neoplasm Staging | |
| Quinazolines -- adverse effects -- therapeutic use | |
| Receptor, ErbB-2 -- metabolism | |
| Survival Analysis | |
| Treatment Outcome | |
| Note générale: | SCOPUS: ar.j |
| Langue: | Anglais |
| Identificateurs: | urn:issn:1470-2045 |
| info:doi/10.1016/S1470-2045(14)70320-1 | |
| info:pii/S1470204514703201 | |
| info:scp/84908602324 | |
| info:pmid/25130998 |



